HomepageIMMP • NASDAQ
add
Immutep Ltd - ADR
$ 1,94
Na sluitingstijd:(0,00%)0,00
$ 1,94
Gesloten: 13 jan, 18:50:22 GMT-5 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 2,01
Dag-range
$ 1,93 - $ 2,01
Jaar-range
$ 1,66 - $ 3,34
Beurswaarde
282,77 mln. USD
Gem. volume
137,34K
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 865,57K | -4,89% |
Bedrijfskosten | 2,03 mln. | -10,92% |
Netto inkomsten | -10,74 mln. | -11,49% |
Netto winstmarge | -1,24K | -17,23% |
Winst per aandeel | — | — |
EBITDA | -11,21 mln. | -17,52% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (AUD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 181,88 mln. | 47,37% |
Totale activa | 201,58 mln. | 36,71% |
Totale passiva | 12,06 mln. | 9,82% |
Totaal aandelenvermogen | 189,52 mln. | — |
Uitstaande aandelen | 1,45 mld. | — |
Koers-boekwaardeverhouding | 15,46 | — |
Rendement op activa | -14,53% | — |
Rendement op kapitaal | -15,32% | — |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -10,74 mln. | -11,49% |
Operationele kasstroom | -8,19 mln. | 30,16% |
Kasstroom uit beleggingen | -10,30 mln. | -87.445,92% |
Kasstroom uit financiering | 47,81 mln. | 25,58% |
Nettomutatie in liquide middelen | 29,03 mln. | 5,47% |
Vrije kasstroom | -6,10 mln. | -44,31% |
Over
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Opgericht
2001
Website
Werknemers
19
